Lupin receives UK nod for Luforbec, first branded generic to Fostair
The UK subsidiary of Indian drugmaker Lupin Limited (BSE: 500257) today announced it has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to market Luforbec (beclomethasone/formoterol) 100/6 dose pressurized metered dose inhaler (pMDI), the first branded generic of Fostair, made by privately-held Italian drugmaker Chiesi Farmaceutici, which has the potential to offer significant cost savings for the National Health Service (NHS).
Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of chronic obstructive pulmonary disease (COPD) (FEV1 <50% predicted normal). Luforbec has the same licensed indications as Fostair 100/6 pMDI. It also has the same active ingredients, an extra fine formulation, and similar device characteristics to Fostair 100/6 pMDI.
NHS spent £179 million in Fostair
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze